Supreme Court, Diageo Rum, Bieber: Intellectual Property

The U.S. Supreme Court agreed to hear an appeal by Teva Pharmaceutical Industries Ltd. in a move that may delay generic competition to its top-selling Copaxone multiple-sclerosis drug and alter how patent appeals are handled.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.